- Home
- TUSK vs RIGL Comparison
TUSK vs RIGL Comparison
Compare TUSK & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TUSK
- RIGL
- Stock Information
- Founded
- TUSK 2014
- RIGL 1996
- Country
- TUSK United States
- RIGL United States
- Employees
- TUSK N/A
- RIGL N/A
- Industry
- TUSK Oilfield Services/Equipment
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- TUSK Energy
- RIGL Health Care
- Exchange
- TUSK Nasdaq
- RIGL Nasdaq
- Market Cap
- TUSK 211.8M
- RIGL 247.1M
- IPO Year
- TUSK 2016
- RIGL 2000
- Fundamental
- Price
- TUSK $3.23
- RIGL $25.04
- Analyst Decision
- TUSK
- RIGL Buy
- Analyst Count
- TUSK 0
- RIGL 5
- Target Price
- TUSK N/A
- RIGL $31.30
- AVG Volume (30 Days)
- TUSK 99.9K
- RIGL 288.9K
- Earning Date
- TUSK 11-01-2024
- RIGL 11-07-2024
- Dividend Yield
- TUSK N/A
- RIGL N/A
- EPS Growth
- TUSK N/A
- RIGL N/A
- EPS
- TUSK N/A
- RIGL 0.22
- Revenue
- TUSK $187,514,000.00
- RIGL $157,374,000.00
- Revenue This Year
- TUSK N/A
- RIGL $38.26
- Revenue Next Year
- TUSK $2.48
- RIGL $24.21
- P/E Ratio
- TUSK N/A
- RIGL $109.79
- Revenue Growth
- TUSK N/A
- RIGL 21.65
- 52 Week Low
- TUSK $2.50
- RIGL $7.48
- 52 Week High
- TUSK $4.95
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- TUSK 30.37
- RIGL 68.80
- Support Level
- TUSK $3.15
- RIGL $22.33
- Resistance Level
- TUSK $3.74
- RIGL $29.16
- Average True Range (ATR)
- TUSK 0.18
- RIGL 2.30
- MACD
- TUSK -0.05
- RIGL 0.41
- Stochastic Oscillator
- TUSK 9.41
- RIGL 69.96
About TUSK Mammoth Energy Services Inc.
Mammoth Energy Services Inc is an integrated, growth oriented energy services company engaged in providing products and services to enable the exploration and development of North American onshore unconventional oil and natural gas reserves as well as the construction and repair of the electric grid for private utilities, public investor-owned utilities, and co-operative utilities through infrastructure services businesses. Its suite of services includes well-completion services, infrastructure services, natural sand proppant services, drilling services, and other services. The majority of revenues are earned from the well-completion services and geographically from the United States followed by Canada and other countries.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.